Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 31 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 27 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 8 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2020 Filed Nov 4, 2020 22:31 UTC | SaleCommon Stock | 1,732 | $39.84 | $68,997.51 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 6 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.805 to $39.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| November 03, 2020 Filed Nov 4, 2020 22:31 UTC | Exercise / conversionCommon Stock | 1,732 | $4.48 | $7,759.36 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 5 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · derivative · entry 11 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,997 Underlying: Common Stock · 35,000 shares Expires 2029-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option vested as to 1/4th of the total shares on March 15, 2020, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
|
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | SaleCommon Stock | 400 | $38.44 | $15,374.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 4 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 602 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
|
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | SaleCommon Stock | 14,445 | $37.86 | $546,909.37 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 3 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,002 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | SaleCommon Stock | 20,155 | $36.79 | $741,448.03 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 2 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,447 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.43 to $37.36 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| November 02, 2020 Filed Nov 4, 2020 22:31 UTC | Exercise / conversionCommon Stock | 35,000 | $4.48 | $156,800.00 |
DisclosureSEC source: 0001209191-20-056953 · doc4.xml · nonDerivative · entry 1 Tulipano Stephen J · CIK 0001360548 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 602 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
|
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,211 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 2,536 | $37.98 | $96,324.89 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.41 to $38.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 3,164 | $36.59 | $115,785.00 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,536 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.355 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 22:30 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-056950 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,503 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · derivative · entry 9 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,386 Underlying: Common Stock · 1,503 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 3/48th of the total shares on January 22, 2019, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 30,497 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · derivative · entry 8 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,069 Underlying: Common Stock · 30,497 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
SaleCommon Stock | 7,225 | $38.42 | $277,585.95 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 6 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $38.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
SaleCommon Stock | 24,775 | $37.64 | $932,578.07 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 5 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,725 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.18 to $38.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionCommon Stock | 1,503 | $2.19 | $3,291.57 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 4 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionCommon Stock | 30,497 | $0.60 | $18,298.20 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,851 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · derivative · entry 7 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,566 Underlying: Common Stock · 5,851 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
SaleCommon Stock | 5,851 | $40.00 | $234,041.76 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2020 Filed Oct 20, 2020 20:52 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionCommon Stock | 5,851 | $0.60 | $3,510.60 |
DisclosureSEC source: 0001209191-20-055378 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:43 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,649 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-20-054703 · doc4.xml · derivative · entry 3 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,417 Underlying: Common Stock · 1,649 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:43 UTC |
Liau GeneEVP Research & Preclinical Dev
|
SaleCommon Stock | 1,649 | $40.00 | $65,960.00 |
DisclosureSEC source: 0001209191-20-054703 · doc4.xml · nonDerivative · entry 2 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 13, 2020 Filed Oct 13, 2020 21:43 UTC |
Liau GeneEVP Research & Preclinical Dev
|
Exercise / conversionCommon Stock | 1,649 | $0.60 | $989.40 |
DisclosureSEC source: 0001209191-20-054703 · doc4.xml · nonDerivative · entry 1 Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,911 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 2,300 | $34.86 | $80,182.60 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.635 to $35.00 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 3,400 | $34.33 | $116,717.92 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.61 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:12 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-053732 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:21 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 17,201 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · derivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,611 Underlying: Common Stock · 17,201 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:21 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 17,201 | $30.00 | $516,030.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 22:21 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 17,201 | $2.19 | $37,670.19 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:21 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,718 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · derivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,812 Underlying: Common Stock · 30,718 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:21 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 30,718 | $30.00 | $921,540.00 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:21 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 30,718 | $2.19 | $67,272.42 |
DisclosureSEC source: 0001209191-20-050031 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,530 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 700 | $28.71 | $20,097.63 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.53 to $29.06 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 5,000 | $27.60 | $138,015.00 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $27.84 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 22:35 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-049551 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:04 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,081 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-048841 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,230 Underlying: Common Stock · 2,081 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:04 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 2,081 | $30.00 | $62,430.00 |
DisclosureSEC source: 0001209191-20-048841 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 28, 2020 Filed Aug 31, 2020 22:04 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 2,081 | $2.19 | $4,557.39 |
DisclosureSEC source: 0001209191-20-048841 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2020 Filed Jan 27, 2021 22:19 UTC |
Menzel Garry EDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 29,555 | $0.00 Strike: $28.57 | $0.00 |
DisclosureSEC source: 0001209191-21-005724 · doc4.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,555 Underlying: Common Stock · 29,555 shares Expires 2030-08-13 F1 · derivative.exercise_date: The option vested as to 1/12th of the total shares on November 13, 2020, and then 1/12th of the total shares vest quarterly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:59 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-044723 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,311 Underlying: Common Stock · 5,700 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:59 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 5,700 | $24.73 | $140,943.33 |
DisclosureSEC source: 0001209191-20-044723 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.03 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 20:59 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-20-044723 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 22:02 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-042943 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,011 Underlying: Common Stock · 1,900 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 22:02 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 1,900 | $25.06 | $47,614.00 |
DisclosureSEC source: 0001209191-20-042943 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 22:02 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionCommon Stock | 1,900 | $2.19 | $4,161.00 |
DisclosureSEC source: 0001209191-20-042943 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 21:41 UTC |
Nash Huw M.COO & CBO
|
SaleCommon Stock | 913 | $22.41 | $20,456.86 |
DisclosureSEC source: 0001209191-20-042004 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.64 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 913 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 21:43 UTC |
Walker Robin A.Chief Legal Officer, CCO & Sec
|
SaleCommon Stock | 941 | $22.50 | $21,172.50 |
DisclosureSEC source: 0001209191-20-042007 · doc4.xml · nonDerivative · entry 1 Walker Robin A. · CIK 0001790807 · Chief Legal Officer, CCO & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 941 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:08 UTC |
Nash Huw M.COO & CBO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-040613 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,911 Underlying: Common Stock · 3,800 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.